211 related articles for article (PubMed ID: 15324875)
1. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
[TBL] [Abstract][Full Text] [Related]
2. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
3. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.
Bernardelli P; Lorthiois E; Vergne F; Oliveira C; Mafroud AK; Proust E; Pham N; Ducrot P; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Chevalier E; Descours A; Berlioz-Seux F; Berna P; Li M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4627-31. PubMed ID: 15324877
[TBL] [Abstract][Full Text] [Related]
4. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
[TBL] [Abstract][Full Text] [Related]
5. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.
Kempson J; Pitts WJ; Barbosa J; Guo J; Omotoso O; Watson A; Stebbins K; Starling GC; Dodd JH; Barrish JC; Felix R; Fischer K
Bioorg Med Chem Lett; 2005 Apr; 15(7):1829-33. PubMed ID: 15780616
[TBL] [Abstract][Full Text] [Related]
6. Orally active PDE4 inhibitor with therapeutic potential.
Ochiai H; Ohtani T; Ishida A; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Eur J Med Chem; 2004 Jul; 39(7):555-71. PubMed ID: 15236836
[TBL] [Abstract][Full Text] [Related]
7. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
[TBL] [Abstract][Full Text] [Related]
8. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
9. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
Deninno MP; Andrews M; Bell AS; Chen Y; Eller-Zarbo C; Eshelby N; Etienne JB; Moore DE; Palmer MJ; Visser MS; Yu LJ; Zavadoski WJ; Michael Gibbs E
Bioorg Med Chem Lett; 2009 May; 19(9):2537-41. PubMed ID: 19339180
[TBL] [Abstract][Full Text] [Related]
10. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
Sawanishi H; Suzuki H; Yamamoto S; Waki Y; Kasugai S; Ohya K; Suzuki N; Miyamoto K; Takagi K
J Med Chem; 1997 Sep; 40(20):3248-53. PubMed ID: 9379444
[TBL] [Abstract][Full Text] [Related]
11. Orally active PDE4 inhibitors with therapeutic potential.
Ochiai H; Ohtani T; Ishida A; Kishikawa K; Obata T; Nakai H; Toda M
Bioorg Med Chem Lett; 2004 Mar; 14(5):1323-7. PubMed ID: 14980691
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
13. New orally active PDE4 inhibitors with therapeutic potential.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and novel derivatives free of positional isomers. Potent inhibitors of cAMP-specific phosphodiesterase and of malignant tumor cell growth.
Merz KH; Marko D; Regiert T; Reiss G; Frank W; Eisenbrand G
J Med Chem; 1998 Nov; 41(24):4733-43. PubMed ID: 9822544
[TBL] [Abstract][Full Text] [Related]
15. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors.
Barnes MJ; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Galvin FC; Gowers L; Haughan AF; Lowe C; Meissner JW; Montana JG; Morgan T; Picken CL; Watson RJ
Bioorg Med Chem Lett; 2001 Apr; 11(8):1081-3. PubMed ID: 11327595
[TBL] [Abstract][Full Text] [Related]
17. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.
Verhoest PR; Proulx-Lafrance C; Corman M; Chenard L; Helal CJ; Hou X; Kleiman R; Liu S; Marr E; Menniti FS; Schmidt CJ; Vanase-Frawley M; Schmidt AW; Williams RD; Nelson FR; Fonseca KR; Liras S
J Med Chem; 2009 Dec; 52(24):7946-9. PubMed ID: 19919087
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 4 regulation of cyclic AMP in pulmonary remodelling: potential roles for isoform selective inhibitors.
Shepherd MC
Pulm Pharmacol Ther; 2006; 19(1):24-31. PubMed ID: 16046159
[No Abstract] [Full Text] [Related]
19. Identification of purine inhibitors of phosphodiesterase 7 (PDE7).
Pitts WJ; Vaccaro W; Huynh T; Leftheris K; Roberge JY; Barbosa J; Guo J; Brown B; Watson A; Donaldson K; Starling GC; Kiener PA; Poss MA; Dodd JH; Barrish JC
Bioorg Med Chem Lett; 2004 Jun; 14(11):2955-8. PubMed ID: 15125967
[TBL] [Abstract][Full Text] [Related]
20. Cyclic AMP phosphodiesterase 4 isoenzyme inhibitory activity of (R)- and (S)-isomer of 7-methyl- or 8-alkyl-4,5,7,8-tetrahydroimidazo[2,1-i]- purin-5-one.
Suzuki H; Nomura M; Miyamoto K; Sawanishi H; Yamamoto K
Biol Pharm Bull; 2004 Mar; 27(3):357-60. PubMed ID: 14993802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
